Elekta makes stereotactic radiosurgery and radiotherapy systems, including the Leksell Gamma Knife and linear accelerators such as Versa HD, along with the software that plans and delivers the treatment. The moat sits in installed base and clinical workflow: hospitals that have standardised on Elekta equipment and software face high switching costs, and the company's service and upgrade revenue recurs over the life of each system. The near-term story is a cyclical recovery in capital equipment orders, since hospital capex has been constrained and revenue is currently shrinking, with reported revenue growth at -3.0%. At 11.6x forward earnings with a 39.6% gross margin and a 10.5% operating margin, the market is pricing in a weak top line, so a return to order growth would be the main thing to test. Trailing P/E is not meaningful and ROE is negative at -4.3%, which is worth checking against the balance sheet before anything else.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 23 Oct 2026, 01:53 CEST | ACCE price target | kr 68.00 | first publication | kr 56.30 |
| 22 Oct 2026, 14:04 CEST | Fair value | kr 51.04 | first publication | kr 55.80 |
| 22 Oct 2026, 14:04 CEST | Rating | Fairly valued | first publication | kr 55.80 |
Answered from Elekta AB (publ) fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| EKTA-B.ST Elekta AB (publ) | kr 57.60 | kr 51 | 13% above | - | -4.3% | 39 | 51 |
| GN.CO GN Store Nord | kr 108.45 | kr 102 | 6% above | - | 2.1% | 37 | 46 |
| AMBU-B.CO Ambu A/S | kr 79.60 | - | - | - | 0.0% | 50 | 37 |
| NOLA-B.ST Nolato AB (publ) | kr 56.10 | kr 42 | 34% above | 20.8x | 13.1% | 64 | 51 |
| VITR.ST Vitrolife AB (publ) | kr 102.70 | kr 111 | 7% below | - | -46.5% | 56 | 39 |
| HAE Haemonetics Corporation Common Stock | $116.16 | $68 | 72% above | 56.7x | 11.2% | 57 | 62 |
| MCAP.ST MedCap AB (publ) | kr 546.00 | kr 385 | 42% above | 34.1x | 16.4% | 68 | 67 |
Where EKTA-B.ST ranks against its sector peers on each metric.